{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifx2icaqzt76zxs65mtp6fjkc5pauxg2vplj2mim64u2nzvzk326q",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3meu27t25mjd2"
  },
  "path": "/2026/02/14/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-colorectal-cancer-of-biparatopic-her2-targeting-adc-jskn003/",
  "publishedAt": "2026-02-14T12:58:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SUZHOU, China, Feb. 14, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of HER2-positive advanced colorectal cancer (CRC). JSKN003 is independently developed by the Company, and […]",
  "title": "Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003"
}